The clinical manifestations of Wilson's disease are due to the accumulation of toxic amounts of copper in the liver, kidney, brain, cornea, and other tissues. Treatment with D-penicillamine (dimethylcysteine), combined with a low copper diet, first Treatment. Soon after confirmation of the diagnosis of Wilson's disease the patients were treated with Dpenicillamine and a low copper diet was prescribed. The drug was given in three divided doses with meals. The initial dose was 500 mg daily, except for patient 1 who received 300 mg. This dose was maintained during the first six months in patients 2, 3, and 4, after which a challenge dose was given equal to the maintenance dose +250 mg. Dependent upon the results obtained, the maintenance dose was increased or continued unchanged.
Methods. Liver function tests were carried out by standard methods. Serum and 24 hour urine samples for zinc and copper assays were collected in metal free containers at monthly intervals during the first year and at bimonthly intervals thereafter. All metal analyses were performed in duplicate by means of atomic absorption spectrophotometry.
Results
Clinical course. All Copper and zinc data. Serum copper concentrations decreased steadily during treatment from 8-0 to 4.4, to 3.1, 11.4 to 1.9, and 10 1 to less than 1 5 imol/l in patients 1, 2, 3, and 4 respectively. Serum zinc concentrations, which were initially high (mean 27 imol/l, range 38 to 22 ,umol/l) followed the same trend and reached the low normal range (mean iimol/l, range 12 to 13-3 iimoll1) during maintenance treatment. The lowest value (14) 2-17 (0-6) (25) urinary zinc copper ratios increased with the duration of treatment as shown in the Table. At the end of the first phase of treatment (usually after more than six months) a challenge dose of Dpenicillamine resulted in a rise in zinc excretion. No further increase in copper excretion was then observed, suggesting that copper elimination was adequate. During the initial phase, however, this challenge dose did cause a rise in copper excretion as shown in patients 3 and 4, four and five months respectively after the start of treatment.
Discussion
The data obtained show that D-penicillamine alters the excretion of both copper and zinc in patients with Wilson's disease. The extent of this is not only dose dependent but is also related to the efficacy of copper elimination. A comparison of the dissociation constants for metal-penicillamine complexes show a decreasing stability in the order Hg> Cu> Ag> Pb> Ni> Cd> Zn> Co> Fe> Mn. Consequently more copper is excreted than zinc in the copper loaded patient at the beginning of treatment. As the mass of copper decreases, zinc having a lower affinity constant but being in relatively greater abundance will be excreted in greater amounts. Therefore, increased zincuria during D-penicillamine challenge is important both in assessing the benefits of treatment and the risks of inducing zinc as well as other trace metal deficiencies.
The effectiveness of treatment is usually assessed by serial determinations of transaminases, serum copper, and 24 hour urinary copper excretion.3 5 6 Our observations confirm previous reports (in children as well as in adults) that serum copper falls with time, as the non-ceruloplasmin bound fraction of serum copper returns to normal.' 7 
